This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Statin Therapy Results in the Real World Practice in the Czech Republic (STEP)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: January 25, 2010
Last updated: August 29, 2011
Last verified: August 2011

Statins are the first choice treatment of dyslipidemia, a major contributor to cardiovascular diseases. Statins also have enough evidence to demonstrate decrease of morbidity and mortality from cardiovascular diseases. Even though statin therapy is effective treatment of dyslipidaemia not all patients reach the goal levels.

The aim of the study is to estimate proportion of patients who achieved the therapeutic goal (LDL-C. total cholesterol, HDL-C and triglycerides levels) after at least one year of a statin therapy.


Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Statin Therapy Results in the Real World Practice in the Czech Republic

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • LDL-C [ Time Frame: one year ]

Secondary Outcome Measures:
  • Total cholesterol [ Time Frame: one year ]
  • HDL-C [ Time Frame: one year ]
  • triglycerides [ Time Frame: one year ]

Estimated Enrollment: 3253
Study Start Date: February 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
specialist care clinics

Inclusion Criteria:

  • Documented statin therapy for at least 12 months
  • Available two LDL-C values: one at the beginning of statin therapy or at the time when patient comes to a specialist; and the other one at least after 12 months of treatment. The latter value should not be older than 6 months.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01055977

  Show 103 Study Locations
Sponsors and Collaborators
Study Director: Ales Kminek AstraZeneca
Principal Investigator: Jaromir Hradec General faculty hospital Prague
Principal Investigator: Jan Bultas Faculty hospital Kralovske Vinohrady Prague
  More Information

Responsible Party: AstraZeneca Identifier: NCT01055977     History of Changes
Other Study ID Numbers: NIS-CCZ-CRE-2009/1
Study First Received: January 25, 2010
Last Updated: August 29, 2011

Keywords provided by AstraZeneca:
statin therapy
treatment goal

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases processed this record on August 18, 2017